Sort
166,118 grants matching “stem cells”
Cilia in Heart Development and Disease
$742,586Martina Brueckner · Yale University · R35 · FY2020 · HL
Biomarkers, mechanisms and modulation of oxidative stress associated risk factors in carcinogenesis
$742,568Yun Rose Li · Beckman Research Institute/City Of Hope · DP5 · FY2025 · OD
Project 1 CaMKK2 a novel target to mitigate radiation induced injury of the hematopoietic system and the gastrointestinal tract
$742,538Nelson J. Chao · Duke University · U19 · FY2020 · AI
Elucidating the SCP4 pathway as a multi-catalytic signaling dependency in acute myeloid leukemia
$742,538Christopher Vakoc · Cold Spring Harbor Laboratory · R01 · FY2023 · CA
The Epigenetics of Alzheimer's Disease
$742,500Li-Huei Tsai · Massachusetts Institute Of Technology · R01 · FY2014 · NS
COMPREHENSIVE CANCER CENTER CORE SUPPORT GRANT
$742,500Barry P Sleckman · University Of Alabama At Birmingham · P30 · FY2020 · CA
Novel Biologic Therapies for BMT: Mechanistic Evaluation in Rhesus Macaques
$742,484Leslie S Kean · Seattle Children'S Hospital · R01 · FY2016 · HL
IONIZING RADIATION EXPOSURE IS KNOWN TO DRAMATICALLY INCREASE THE LEVEL OF REACTIVE OXYGEN SPECIES (ROS) IN HUMAN CELLS. ROS HAVE BEEN IMPLICATED AS KEY CONTRIBUTORS TO NUMEROUS PATHOPHYSIOLOGICAL DISORDERS INCLUDING CANCER HEART FAILURE NEURO-DEGENERATION ETC. VIA STIMULATING AUTOPHAGY DEATH DNA DAMAGE MITOCHONDRIAL DYSFUNCTION OR PROTEIN DEACTIVATION WITHIN CELLS. IN RECENT YEARS ANTIOXIDANTS SUCH AS CURCUMIN (CCM) N-ACETYL CYSTEINE (NAC) AND N-MERCAPTOPROPIONYL GLYCINE (NMPG) HAVE BEEN DISCOVERED TO NEUTRALIZE FREE RADICALS AND PROTECT CELLS FROM THE INSULT-INDUCED DAMAGE. WITH NASA S CURRENT INTERESTS IN RETURNING TO THE MOON AND MISSIONS TO MARS ASTRONAUTS WOULD BE EXPOSED TO INCREASED AMOUNTS OF IONIZING RADIATION DUE TO THE LONG DURATIONS OF FLIGHTS.THUS THIS PROJECT SEEKS TO USE NOVEL DRUG DELIVERY SYSTEMS FOR EFFICIENT UPTAKE OF CCM NAC AND N-MPG INTO CELLS: 1) FUSOGENIC LIPOSOMES CONSTRUCTED FROM THE SAME BIOMATERIALS THAT CONSTITUTE CELL MEMBRANES; 2) ALBUMIN THE MOST ABUNDANT BLOOD PROTEIN; AND 3) CHITOSAN A FDA-APPROVED POLYSACCHARIDE. THESE PARTICLE SYSTEMS WILL BE USED TO INVESTIGATE DRUG RELEASE UPTAKE IN CELLS ANDEFFECTIVENESS (SUCH AS CELL VIABILITY AND PROTEIN EXPRESSION OF DNA DAMAGE AND REPAIR). CELLS AND ANIMALS WILL BE EXPOSED TO EITHER GAMMA RADIATION OR HIGH-ENERGY IRON-ION RADIATION AT BROOKHAVEN NATIONAL LABORATORY. THE PROPOSED DRUG-DELIVERY SYSTEMS HAVE THE CAPABILITY TO PROVIDE SHORT- (MINUTES) AND LONG-TERM (HOURS - DAYS) DELIVERY. A TREMENDOUS BENEFIT TO OUR DELIVERY SYSTEM IS THEABILITY TO TAILOR DRUG THERAPY TO ACCURATELY CORRESPOND TO THE LEVEL AND DURATION OF RADIATION EXPOSURE. ALL OTHER METHODOLOGIES HAVE PURSUED A ONE-SIZE FITS ALL APPROACH WHICH MAY NOT DELIVER AN APPROPRIATE DOSE TO MITIGATE ADVERSE EVENTS. OUR DELIVERY SYSTEM WILL RESCUE IRRADIATED CELLS VIA THE INTRODUCTION OF DRUGS TO MITIGATE THE EFFECTS OF THE IONIZING RADIATION. THE DESIGN OF COUNTERMEASURESFOR MITIGATION OF OXIDATIVE STRESS DAMAGE IS CRUCIAL FOR PROTECTION OF ASTRONAUT HEALTH. RADIATION MITIGATION RESEARCH ALIGNS WITH THE HUMAN EXPLORATION AND OPERATIONS MISSION DIRECTORATE DIRECTLY ADDRESSING THE HUMAN RESEARCH PROGRAM OF INTEGRATED RESEARCH PLAN SPACE RADIATION RISK: 1.2 RISK OF ACUTE RADIATION SYNDROMES DUE TO SOLAR PARTICLE EVENTS 1.3 RISK OF DEGENERATIVE TISSUE OR OTHER HEALTH EFFECTS FROM RADIATION EXPOSURE 1.4 RISK OF RADIATION CARCINOGENESIS FROM SPACE RADIATION AND EXPLORATIONMEDICAL CAPABILITY RISK: 1.1 INABILITY TO ADEQUATELY RECOGNIZE OR TREAT AN ILL OR INJURED CREW MEMBER. THE PROPOSED STUDIES FOCUS SPECIFICALLY ON DEGENERATIVE TISSUE - GAPS DEGEN #6; ACUTE RADIATION SYNDROMES GAPS ACUTE #7; RADIATION CARCINOGENESIS GAPS CANCER #8; AND EXPLORATION MEDICAL CAPABILITY GAP EXMC #4.22. THE PROPOSED WORK ALSO ALIGNS WITH KY SCIENCE AND TECHNOLOGY STRATEGIC PLANS BY PROPOSING SPACE-RELATED RESEARCH WHILE PROVIDING OPPORTUNITIES FOR EDUCATION TO A DIVERSE GROUP IN AMULTIDISCIPLINARY SUBJECT AREA. THE PROPOSED WORK INCLUDES TRAINING OF PH.D. STUDENTS AND POSTDOCTORAL FELLOWS THUS STRENGTHENING EDUCATIONAL OPPORTUNITIES IN STEM FIELDS IN KY. THE RESEARCH TEAM CONSISTS OF 3 FEMALES AND 3 MINORITY MEMBERS STRENGTHENING THE PARTICIPATION OF UNDERREPRESENTED GROUPS. TWO OF THE POSTDOCS ARE KY NATIVES WHICH ALIGNS WITH KEEPING TALENT WITHIN KY ANDSTRENGTHENING THE COMPETITIVE AND PRODUCTIVE COMMUNITY OF ACADEMIC SCIENTISTS. IN ADDITION THE WORK IS COLLABORATION AMONG THE SCHOOL OF ENGINEERING (BIOENGINEERING) SCHOOL OF MEDICINE (DEPARTMENT OF MEDICINE) AND INDUSTRY (EDS INC.) WHICH INCREASES FACULTY-INDUSTRY PARTNERSHIPS THAT HAVE COMMERCIAL POTENTIAL WHILE STRENGTHENING KY S SCIENCE AND RESEARCH CAPACITY IN PRIORITY STEM AREAS. IN ADDITION NASA COLLABORATORS FROM JSC WILL STRENGTHEN THE LINKAGES BETWEEN KY RESEARCHERS AND NASA CENTERS R&D PROGRAMS AND MISSIONS.
$742,484University Of Kentucky Research Foundation, The · · FY2014 · National Aeronautics and Space Administration
Defining gene regulatory networks driving cortical evolution and brain development
$742,453Luis De La Torre-Ubieta · University Of California Los Angeles · R01 · FY2025 · MH
ABI Innovation: Domain Architecture Simulator
$742,448Marie Dannie Durand · Carnegie Mellon University · · FY2018 · BIO
Cancer and Leukemia Group B - Leukemia Correlative Sciences
$742,430Guido Marcucci · Ohio State University · U10 · FY2013 · CA
Genomics of Post-Operative Atrial Fibrillation After Cardiac Surgery
$742,415Jochen Daniel Muehlschlegel · Brigham And Women'S Hospital · R01 · FY2022 · HL
Clinical and Basic Science Studies in Long QT Syndrome Type 3
$742,413Arthur J. Moss · University Of Rochester · R01 · FY2014 · HL
Developmental Regulatory Genomics of Human Cardiovascular Lineages
$742,409Sylvia M Evans · University Of California, San Diego · UM1 · FY2019 · HL
Modelling the dynamics of spontaneous clonal hematopoiesis in pet dogs during cancer therapy
$742,391Cheryl A London · Tufts University Boston · R01 · FY2025 · CA
Functional studies of Forkhead transcription factors in mesoderm development
$742,347Alan Michelson · National Heart, Lung, And Blood Institute · ZIA · FY2012 · HL
Developing second generation SCID pig models: filling the gaps to improve translation of therapeutics in regenerative medicine
$742,315Christopher Tuggle · Iowa State University · R24 · FY2021 · OD
Phase 2 Pediatric Autologous BMMNC for Severe TBI
$742,313Charles S Cox · University Of Texas Hlth Sci Ctr Houston · R01 · FY2015 · NS
Injectable microgel for soft tissue repair
$742,307Joseph C. Salamone · Rochal Industries, Llp · R44 · FY2014 · GM
Assay of chemicals for Parkinson's toxicity in human iPSC-derived neurons
$742,257Patrick M McDonough · Vala Sciences, Inc. · R44 · FY2019 · ES
Genetic determinants of 4D genome folding in human cardiac development
$742,240Benoit Gaetan Bruneau · J. David Gladstone Institutes · U01 · FY2020 · HL
Targeting abnormal alveolar immune activation and failed epithelial repair in COVID-19
$742,194Alexander Misharin · Northwestern University At Chicago · R01 · FY2023 · HL
Targeting abnormal alveolar immune activation and failed epithelial repair in COVID-19
$742,194Alexander Misharin · Northwestern University At Chicago · R01 · FY2022 · HL
Human microtissues for in situ detection and functional measurement of adverse consequences caused by genome editing
$742,185Todd C McDevitt · J. David Gladstone Institutes · U01 · FY2018 · HL
Molecular mechanism of thyroid hormone receptor function during metamorphosis
$742,159Yun-Bo Shi · Eunice Kennedy Shriver National Institute Of Child Health & Human Development · ZIA · FY2018 · HD